Omnio Secures €2.9 Mn to Advance Plasminogen Therapy for Chronic Wounds

Omnio will use the new funding to further develop its plasminogen-based treatment for chronic wounds that are difficult to heal. The company plans to use the funding to move the therapy closer to clinical studies.

“This financing demonstrates our continuous progress and strong confidence from our current investors. Their support allows us to continue the development and puts us in a stronger position ahead of our next financing round for clinical studies,” said Felipe Velasquez, CEO of Omnio.

Omnio was founded based on research by Professor Tor Ny at Umeå University, who also leads the company’s R&D work. The biotech startup is developing plasminogen-based treatments for chronic wounds and other related conditions.

Omnio is working on a biological treatment designed to target the underlying causes of poor wound healing. The company aims to develop therapies that can help wounds heal when the normal healing process is impaired.

Omnio’s main treatment focus is diabetic foot ulcers (DFUs), which can be difficult to heal and have limited treatment options. The company says more than 500 million people worldwide live with diabetes, and up to one in three may develop a foot ulcer during their lifetime.

Read Also- StudyStash Acquired by Kortext to Expand AI-Powered Learning Solutions